Hematocrit elevation associated with testosterone administration

Journal of the American Medical Directors Association

Volumn 14, Issue 11, 2013, Pages 848-

  Drinka, Paul ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; TESTOSTERONE;

ANDROGEN THERAPY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EDEMA; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; HYPOGONADISM; LETTER; NURSING HOME; NURSING HOME PATIENT; POLYCYTHEMIA VERA; PROSTATE CANCER; SIDE EFFECT; SLEEP DISORDERED BREATHING;

ANDROGENS; HUMANS; HYPOGONADISM; MALE; TESTOSTERONE;

EID: 84886800896     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2013.08.006     Document Type: Letter

References (10)

1. Morley J.E. Hypogonadism, testosterone, and nursing home residents [editorial]. JAm Med Dir Assoc 2013, 14:381-383.
2. Drinka P.J., Jochen A.L., Cuisinier M., et al. Polycythemia as a complication of testosterone replacement therapy in nursing home men with low testosterone levels. JAm Geriatr Soc 1995, 43:899-901.
3. Bhasin S., Cunningham G.R., Hayyes F.J., et al. Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society Clinical Practice Guideline. JClin Endocrinol Metab 2010, 95:2536-2559.
4. Buvat J., Maggi M., Guay A., et al. Testosterone deficiency in men: Systematic review and standard operating procedures for diagnosis and treatment. JSex Med 2013, 10:245-284.
5. Dobs A.S., Meikle A.W., Arver S. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. JClin Endocrinol Metab 1999, 84:3469-3478.
6. Coviello A.D., Kaplan B., Lakshman K.M. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. JClin Endocrinol Metab 2008, 93:914-919.
7. Basaria S., Coviello A.D., Travison T.G., et al. Adverse events associated with testosterone administration. NEngl J Med 2010, 363:109-122.
8. Marchioli R., Finazzi G., Specchia G. Cardiovascular events and intensity of treatment in polycythemia vera. NEngl J Med 2013, 368:22-33.
9. Locatelli F., Baraney P., Covic A., et al. Kidney disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant 2013, 28:1346-1359.
10. Kunnas T., Solakivi T., Huuskonen K. Hematocrit and the risk of coronary heart disease mortality in the TAMRISK study, a 28-year follow-up. Prev Med 2009, 49:45-47.